Sanofi (NASDAQ:SNY) Holdings Decreased by Kovitz Investment Group Partners LLC

Kovitz Investment Group Partners LLC cut its stake in Sanofi (NASDAQ:SNY - Free Report) by 73.7% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 15,938 shares of the company's stock after selling 44,606 shares during the quarter. Kovitz Investment Group Partners LLC's holdings in Sanofi were worth $769,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently modified their holdings of the company. Synergy Asset Management LLC purchased a new stake in Sanofi during the 4th quarter worth approximately $25,000. McClarren Financial Advisors Inc. increased its stake in shares of Sanofi by 952.6% in the fourth quarter. McClarren Financial Advisors Inc. now owns 600 shares of the company's stock worth $28,000 after buying an additional 543 shares during the last quarter. Bessemer Group Inc. raised its holdings in Sanofi by 59.8% in the fourth quarter. Bessemer Group Inc. now owns 647 shares of the company's stock valued at $32,000 after acquiring an additional 242 shares in the last quarter. Lee Danner & Bass Inc. bought a new position in Sanofi during the 4th quarter valued at $31,000. Finally, Sierra Ocean LLC acquired a new position in Sanofi during the 4th quarter worth $44,000. Hedge funds and other institutional investors own 14.04% of the company's stock.

Analysts Set New Price Targets

Several equities analysts have recently commented on the stock. Sanford C. Bernstein raised shares of Sanofi to a "strong-buy" rating in a research report on Thursday, January 30th. Deutsche Bank Aktiengesellschaft raised Sanofi from a "sell" rating to a "hold" rating in a report on Thursday, January 30th. Hsbc Global Res raised Sanofi to a "strong-buy" rating in a research report on Monday, April 28th. BNP Paribas began coverage on shares of Sanofi in a report on Tuesday, April 15th. They issued an "outperform" rating and a $65.00 price objective for the company. Finally, The Goldman Sachs Group initiated coverage on shares of Sanofi in a report on Friday, March 21st. They set a "neutral" rating and a $65.00 target price on the stock. Three research analysts have rated the stock with a hold rating, two have given a buy rating and three have given a strong buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Buy" and a consensus price target of $63.33.

Sanofi Stock Performance

NASDAQ:SNY traded down $0.41 during midday trading on Tuesday, reaching $54.18. 455,523 shares of the company traded hands, compared to its average volume of 2,339,672. Sanofi has a twelve month low of $45.80 and a twelve month high of $60.12. The company has a debt-to-equity ratio of 0.15, a current ratio of 1.46 and a quick ratio of 1.14. The company has a fifty day moving average price of $54.53 and a 200 day moving average price of $52.03. The firm has a market capitalization of $136.88 billion, a price-to-earnings ratio of 21.74, a price-to-earnings-growth ratio of 1.01 and a beta of 0.55.

Sanofi (NASDAQ:SNY - Get Free Report) last released its quarterly earnings results on Thursday, April 24th. The company reported $0.94 EPS for the quarter, topping the consensus estimate of $0.90 by $0.04. Sanofi had a net margin of 12.77% and a return on equity of 25.61%. The business had revenue of $10.41 billion during the quarter, compared to analyst estimates of $9.79 billion. During the same quarter in the prior year, the firm earned $1.78 earnings per share. The company's quarterly revenue was down 11.0% on a year-over-year basis. On average, analysts expect that Sanofi will post 4.36 EPS for the current fiscal year.

Sanofi Increases Dividend

The firm also recently declared an annual dividend, which will be paid on Thursday, June 12th. Stockholders of record on Friday, May 9th will be issued a dividend of $2.0369 per share. This represents a dividend yield of 3.1%. The ex-dividend date is Friday, May 9th. This is a boost from Sanofi's previous annual dividend of $1.48. Sanofi's payout ratio is 57.14%.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.